Ranolazine: a new approach to treating an old problem.

Article Details

Citation

Copy to clipboard

Reddy BM, Weintraub HS, Schwartzbard AZ

Ranolazine: a new approach to treating an old problem.

Tex Heart Inst J. 2010;37(6):641-7.

PubMed ID

21224931 [ View in PubMed

]

Abstract

Chronic angina pectoris affects millions of patients every year. During the past 2 decades, advances in medical therapy have led to substantial reductions in the symptoms of angina. Nonetheless, many patients continue to experience persistent angina that causes debilitating symptoms and lifestyle changes. Moreover, many current therapeutic agents cause side effects that can induce substantial morbidity on their own. In major clinical trials, the drug ranolazine has been shown to bring symptomatic relief to large numbers of patients who have chronic angina. Herein, we review the physiology of the sodium channel; the pharmacology of ranolazine; clinical trials that support use of the drug; recent evidence about ranolazine's therapeutic effect on diastolic heart failure, glycemic control, and atrial fibrillation and other arrhythmias; officially approved clinical indications; and avenues of future study.

DrugBank Data that Cites this Article

Drugs

Ranolazine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ranolazine	Fatty acid	Group		Unknown	Other/unknown	Details